New CEO at CEVEC Pharmaceuticals GmbH

Cologne, October 2nd, 2008; CEVEC Pharmaceuticals, a
biopharmaceutical company specializing in the development of complex
therapeutic proteins using their proprietary human cell expression
systems, appointed Rainer Lichtenberger Ph.D., MBA as the new Chief
Executive Officer (CEO). Rainer Lichtenberger will replace Prof.
Stefan Kochanek, one of the founders of the company, who led the
company as interim CEO for nearly half a year and will continue to
serve as one of the advisory board members.
With Dr. Lichtenberger, CEVEC has attracted a seasoned life science
manager with 20 years of management experience in renowned companies
such as the Merckle/ratiopharm group and Merck KgaA. There he held
various positions of increasing responsibility, among them
vice-president of strategic marketing and corporate vice-president of
business development. Most recently, he led a private
venture-financed German biopharmaceutical development company, where
he managed a major series A venture round. Dr. Lichtenberger's team
at CEVEC will be complemented by other experienced staff such as Dr.
Christoph Volpers, Chief Operating Officer (COO) and Chief Scientific
Officer (CSO) Dr. Gudrun Schiedner.

Gangolf Ehlen, Investment Manager for Venture Capital Investments of
Sparkasse KölnBonn and chairman of the advisory board of CEVEC
comments: "We are very satisfied that we could win Dr. Lichtenberger
as a senior expert with broad and deep industry experience and
excellent business networks. We see this as further proof of the
attractiveness of CEVEC's unique technology platform. We would like
to thank Prof. Kochanek for his commitment in this transition period
of the company." Prof. Kochanek said: "I am looking forward to
working with Dr. Lichtenberger, whose background in drug development,
business development and experience in a venture financed life
science company fits perfectly into CEVEC's ambitious business
objectives for the next few years.

About CEVEC Pharmaceuticals GmbH:
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in
Cologne, Germany, is a biopharmaceutical company that specializes in
developing and producing therapeutic proteins and monoclonal
antibodies with human glycosylation patterns. CEVEC's novel
proprietary and patent-protected human CAP and PIOS expression
systems are ideal for manufacturing complex biopharmaceutical
molecules, which were previously unavailable or could only be
extracted from plasma or tissue. Covering all steps from the
isolation of primary human cells to establishing specific production
cell lines, CEVEC strictly adheres to the latest quality and
regulatory standards required for therapeutics.
CEVEC is successfully using its proprietary human CAP expression
technology to develop several of its innovative biopharmaceutical
molecules up to the preclinical phase and aims to out-license these
through partnerships with renowned pharmaceutical companies for
further product development and commercialization.

Further information on CEVEC Pharmaceuticals GmbH:
Internet: www.cevec-pharmaceuticals.com
E-Mail: info@cevec-pharmaceuticals.com
Address: CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 62
D-51105 Köln, Germany
phone: *49 221-46020800
fax: *49 221-46020801
Copyright © Hugin AS 2008. All rights reserved.